(Q79969162)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Saeed Zarei

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Shokri F

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

9 November 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

269-276

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Improving birth dose coverage of hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

High rate of seroconversion following administration of a single supplementary dose of recombinant hepatitis B vaccine in Iranian healthy nonresponder neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

DNA vaccines: development, standardization and regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Frequency analysis of HBsAg-specific B lymphocytes in high-responder individuals to recombinant hepatitis B vaccine: comparison of LDA and ELISPOT assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Response to supplementary vaccination with recombinant or plasma hepatitis B vaccine in healthy non-responding children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Hepatitis B revaccination in healthy non-responder Chinese children: five-year follow-up of immune response and immunologic memory.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Immunisation of staff of a regional blood transfusion centre with a recombinant hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule--results of a post-marketing surveillance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Revaccination against hepatitis B virus of non-responding and low-responding infants immunised at birth. A parallel evaluation of rubella and tetanus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Defect in Th1-like cells of nonresponders to hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

HLA-Bw54-DR4-DRw53-DQw4 haplotype controls nonresponsiveness to hepatitis-B surface antigen via CD8-positive suppressor T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Selective unresponsiveness to HBsAg vaccine in newborns related with an in utero passage of hepatitis B virus DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Diminished Th1 and Th2 cytokine production in healthy adult nonresponders to recombinant hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Analysis of T-cell receptor beta chain variable gene segment usage in healthy adult responders and nonresponders to recombinant hepatitis B vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Induction of TH1 and TH2 immunity in neonatal mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

B cells activated via CD40 and IL-4 undergo a division burst but require continued stimulation to maintain division, survival and differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

Safety of immunization and adverse events following vaccination against hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.044

10.1016/J.VACCINE.2007.10.044

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18037544%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference